Carfilzomib-based therapies have been approved for the management of patients with relapsed/refractory multiple myeloma (rrMM) based on the positive results from 2 randomized clinical trials, namely ASPIRE and ENDEAVOR.1-5 Although the 2 trials showed remarkable clinical benefits of carfilzomib-based rrMM treatments, it was still unclear whether these results could translate into routine clinical practice since some patients might not be eligible for the trials. As such, a prospective real-world (RW) study was performed to evaluate the effectiveness of carfilzomib + dexamethasone (Kd) or carfilzomib + lenalidomide + dexamethasone (KRd) in the RW setting among the Asian population, hoping to provide additional insights into the efficacy-effectiveness gap.6 In an interview with Omnihealth Practice, Dr. Kong, Shun-yin Jacky shared his insight into the latest Asian RW data of carfilzomib and presented a clinical case to demonstrate the effectiveness of Kd in rrMM management in the local clinical setting.